Abstract: Described herein are techniques of using machine learning to automatically extract clinical variable values for subjects from clinical record data. The techniques designate certain clinical variables as hybrid variables that can be assigned values by machine learning model prediction. The techniques process, using a machine learning model trained to predict a value of a hybrid variable, clinical record data associated with a subject to obtain a predicted hybrid variable value and an associated confidence score. The techniques set the value of the hybrid variable for the subject to the predicted hybrid variable value when the model prediction is of sufficiently high confidence.

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

Abstract: The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.

Abstract: The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

Abstract: A method is described herein, comprising vaporizing a glycol material by thermal contact with a heating medium to form a vaporized glycol stream, increasing a pressure of the vaporized glycol stream to form a pressurized glycol stream, and increasing a temperature of the heating medium by thermally contacting the heating medium with the pressurized glycol stream.

Abstract: Salts of Compound A and forms described herein are estrogen receptor alpha modulators. Such salts and/or forms can be are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: A syringe assembly includes a syringe barrel (12) having a proximal end and a distal end, a needle hub (20) supporting the needle and coupled to the distal end of the syringe barrel (12). A moveable shield (36) is included for sliding from a first position where the needle is exposed a first length, a second position where the needle is exposed a second length less than said first length, and a third position covering a distal end of the needle. A locking mechanism (48, 86) is included to retain the shield in the second position while enabling the shield to slide to the third position, and to lock the shield in the third position to prevent re-use of the syringe.

Abstract: An adhesive patch is secured to an infusion set, patch pump or other on-body medical device by an overmolding process during manufacture of the medical device, or during manufacture of a portion of the medical device, without the need for a separate adhesive. This provides a more secure connection between the patch and the medical device, and reduces the required number of adhesive layers from two (skin attachment side and device attachment side) to one (skin attachment side only), thereby simplifying the design and manufacture of the patch.

Abstract: An adhesive patch is secured to an infusion set, patch pump or other on-body medical device by an overmolding process during manufacture of the medical device, or during manufacture of a portion of the medical device, without the need for a separate adhesive. This provides a more secure connection between the patch and the medical device, and reduces the required number of adhesive layers from two (skin attachment side and device attachment side) to one (skin attachment side only), thereby simplifying the design and manufacture of the patch.

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

Abstract: A system comprises an imaging device that includes a two dimensional array of pixels. Each pixel of the array includes a first optical filter having a first pass band arranged to filter excitation light reflected by a moving object and a first detector configured to detect light transmitted through the first optical filter and to generate a first electrical signal. Each pixel of the array also includes a second optical filter having a second pass band arranged to filter excitation light reflected by a moving object and a second detector configured to detect light transmitted through the second optical filter and to generate a second electrical signal. The imaging device further includes circuitry that generates output signals from each of the pixels based on the first electrical signal and the second electrical signal of the pixel. The output signal includes information about the speed and direction of the moving object.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.

Abstract: A method of manufacturing a medical device, including forming a flexible base portion to have a plurality of through-holes therethrough, placing the flexible base portion on a non-patient side of an adhesive patch with the through-holes in communication with the adhesive patch, dispensing an adhesive into the through-holes onto the adhesive patch and walls of the flexible base portion surrounding the through-holes; and curing the adhesive to form an adhesive plug mechanically bonding the flexible base portion to the adhesive patch.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting epression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.

Abstract: An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation. In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques.

Abstract: Methods, systems and computer-readable medium are provided for implementing commands by a collaboration system on behalf of participants of an event utilizing such collaboration system. A method includes identifying participants associated with an event conducted using an online collaboration system; generating a per-participant metric for each one of the participants to generate a plurality of metrics; populating each of the plurality of metrics for a corresponding participant using data received from multiple data sources, each data source providing a particular type of data for the corresponding participant and in association with participation of the corresponding participant in the event; determining a command to be performed on behalf of one or more of the participants; determining, using the plurality of metrics, at least one target associated with the command to yield at least one identified target; and performing the command for the at least one target.

Abstract: A method for managing ice accretion on a gas turbine engine component comprises providing an ice management system comprising a de-icing promoter applied to only portions of a gas turbine engine component. The method further comprises operating the ice management system in icing conditions to promote the shedding of ice accreted on the gas turbine engine component on those portions where the de-icing promoter is applied.